IP Library › Granted Patent US 10,640,496
Granted Patent B2
US 10,640,496 · App. 16/310,005 · Granted May 5, 2020

Method for producing diphenylmethane derivative

Inventors: Hee-kyoon Yoon (Cheongju-si, KR); Se-Hwan Park (Yongin-si, KR); Ji-sung Yoon (Yongi-si, KR); Soongyu Choi (Yongin-si, KR); Hee Jeong Seo (Yongin-si, KR); Eun-Jung Park (Yongin-si, KR); Younggyu Kong (Yongin-si, KR); Kwang-Seop Song (Yongin-si, KR); Min Ju Kim (Yongin-si, KR); So Ok Park (Yongin-si, KR)
Assignees: DAEWOONG PHARMACEUTICAL CO., LTD.; GREEN CROSS CORPORATION
C07D409/04B01D9/005C07D307/78C07D407/04C07B51/00C07B2200/13Y02P20/55
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,640,496
App. No.
16/310,005
Granted
May 5, 2020
Kind
B2
Abstract

The present invention relates to an improved method for producing a diphenylmethane derivative which is effective as a sodium-dependent glucose cotransporter (SGLT) inhibitor, the method being carried out by means of a convergent synthesis method in which each major group is separately synthesized and then coupled. As such, in comparison to a linear synthesis method disclosed in existing documents, the synthesis pathway is compact and yield can be increased, and risk factors inherent in the linear synthesis pathway can be reduced. Furthermore, the crystal form of the compound produced according to the method has superb physicochemical characteristics, and thus can be effectively utilized in fields such as pharmaceutical manufacturing.

Claims (8)

1. A crystalline form of a compound of the following Formula c28:

wherein the crystalline form has an X-ray diffraction (XRD) spectrum which includes peaks at diffraction angles (2θ) of 6.2°±0.2°, 7.2°±0.2°, 8.8°±0.2°, 17.6°±0.2°, 19.0°±0.2°, 22.5°±0.2°, and 25.1°±0.2° in a case of being irradiated using a Cu—K α light source.

2. A crystalline form of a compound of the following Formula c28:

wherein the crystalline form has an X-ray diffraction (XRD) spectrum which includes peaks at diffraction angles (2θ) of 7.0°±0.2°, 14.9°±0.2°, 17.7°±0.2°, 18.8°±0.2°, 20.6°±0.2°, 21.8°±0.2°, and 23.5°±0.2° in a case of being irradiated using a Cu—K α light source.

3. A crystalline form of a compound of the following Formula c28:

wherein the crystalline form has an X-ray diffraction (XRD) spectrum which includes peaks at diffraction angles (2θ) of 5.6°±0.2°, 7.3°±0.2°, 15.7°±0.2°, 17.2°±0.2°, 18.9°±0.2°, 21.2°±0.2°, and 21.9°±0.2° in a case of being irradiated using a Cu—K α light source.

4. A crystalline form of a compound of the following Formula c28:

wherein the crystalline form has an X-ray diffraction (XRD) spectrum which includes peaks at diffraction angles (2θ) of 5.5°±0.2°, 7.2°±0.2°, 15.3°±0.2°, 17.2°±0.2°, 17.6°±0.2°, 18.9°±0.2°, and 21.1°±0.2° in a case of being irradiated using a Cu—K α light source.

Assignments (2)
LICENSE Recorded Nov 16, 2022
From: GREEN CROSS CORPORATION
To: DAEWOONG PHARMACEUTICAL CO., LTD.
Reel/Frame 061795/0506 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 26, 2018
From: YOON, HEE-KYOON; PARK, SE-HWAN; YOON, JI-SUNG; CHOI, SOONGYU; SEO, HEE JEONG; PARK, EUN-JUNG; KONG, YOUNGGYU; SONG, KWANG-SEOP; KIM, MIN JU; PARK, SO OK
To: DAEWOONG PHARMACEUTICAL CO., LTD.; GREEN CROSS CORPORATION
Reel/Frame 047853/0435 →
Priority Claims (1)
KR 10-2016-0075910 · Jun 17, 2016 · national
Continuity (1)
Related Publication 20190169174A1 · Jun 6, 2019
Cited By (2)
US 12,448,360 US 12,497,390